Which has preferable valuation and earnings, NPCE or AXGN?

AxoGen has higher revenue and earnings than NeuroPace. AxoGen is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.36 -$21.47M -$0.65 N/A AxoGen $238.11M 8.94 -$15.70M -$0.64 N/A

Is NPCE or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to NeuroPace's net margin of -21.67%. AxoGen's return on equity of -9.63% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% AxoGen -13.21% -9.63% -6.26%

Does the media refer more to NPCE or AXGN?

In the previous week, AxoGen had 5 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for AxoGen and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat AxoGen's score of 0.77 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NPCE or BFLY?

In the previous week, Butterfly Network had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Butterfly Network and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat Butterfly Network's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, NPCE or NVCR?

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.36 -$21.47M -$0.65 N/A NovoCure $655.35M 2.86 -$136.23M -$1.53 N/A

Is NPCE or NVCR more profitable?

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% NovoCure -25.66% -50.82% -16.48%

Does the media refer more to NPCE or NVCR?

In the previous week, NovoCure had 4 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for NovoCure and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat NovoCure's score of -0.01 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NPCE or EYE?

In the previous week, NeuroPace and NeuroPace both had 1 articles in the media. National Vision's average media sentiment score of 1.70 beat NeuroPace's score of 0.87 indicating that National Vision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Vision 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

NeuroPace (NPCE) Competitors

$15.71 -0.04 (-0.25%)

As of 11:41 AM Eastern

Compare

NPCE vs. AXGN, BFLY, NVCR, PLSE, and EYE

Should you buy NeuroPace stock or one of its competitors? MarketBeat compares NeuroPace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroPace include AxoGen (AXGN), Butterfly Network (BFLY), NovoCure (NVCR), Pulse Biosciences (PLSE), and National Vision (EYE). These companies are all part of the "medical equipment" industry.

How does NeuroPace compare to AxoGen?

NeuroPace (NASDAQ:NPCE) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

AxoGen has a net margin of -13.21% compared to NeuroPace's net margin of -21.67%. AxoGen's return on equity of -9.63% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
AxoGen	-13.21%	-9.63%	-6.26%

In the previous week, AxoGen had 5 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for AxoGen and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat AxoGen's score of 0.77 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has higher revenue and earnings than NeuroPace. AxoGen is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.36	-$21.47M	-$0.65	N/A
AxoGen	$238.11M	8.94	-$15.70M	-$0.64	N/A

NeuroPace presently has a consensus price target of $18.83, indicating a potential upside of 19.88%. AxoGen has a consensus price target of $46.50, indicating a potential upside of 16.10%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AxoGen beats NeuroPace on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Butterfly Network?

NeuroPace (NASDAQ:NPCE) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

NeuroPace presently has a consensus price target of $18.83, suggesting a potential upside of 19.88%. Butterfly Network has a consensus price target of $5.56, suggesting a potential downside of 17.41%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NeuroPace has higher revenue and earnings than Butterfly Network. NeuroPace is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.36	-$21.47M	-$0.65	N/A
Butterfly Network	$97.61M	17.57	-$77.06M	-$0.30	N/A

NeuroPace has a net margin of -21.67% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Butterfly Network	-73.63%	-34.41%	-23.91%

In the previous week, Butterfly Network had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Butterfly Network and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat Butterfly Network's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

Summary

NeuroPace beats Butterfly Network on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to NovoCure?

NeuroPace (NASDAQ:NPCE) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.36	-$21.47M	-$0.65	N/A
NovoCure	$655.35M	2.86	-$136.23M	-$1.53	N/A

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
NovoCure	-25.66%	-50.82%	-16.48%

In the previous week, NovoCure had 4 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for NovoCure and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat NovoCure's score of -0.01 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace currently has a consensus target price of $18.83, suggesting a potential upside of 19.88%. NovoCure has a consensus target price of $23.60, suggesting a potential upside of 45.76%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

NeuroPace has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

NeuroPace beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

NeuroPace has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,813.37	-$72.78M	-$1.10	N/A
NeuroPace	$99.99M	5.36	-$21.47M	-$0.65	N/A

Pulse Biosciences currently has a consensus target price of $30.67, suggesting a potential upside of 0.45%. NeuroPace has a consensus target price of $18.83, suggesting a potential upside of 19.88%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Pulse Biosciences has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. Pulse Biosciences' return on equity of -86.67% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
NeuroPace	-21.67%	-108.20%	-18.50%

In the previous week, NeuroPace had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 1 mentions for NeuroPace and 0 mentions for Pulse Biosciences. NeuroPace's average media sentiment score of 0.87 beat Pulse Biosciences' score of 0.59 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulse Biosciences	Positive
NeuroPace	Positive

76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pulse Biosciences has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Summary

NeuroPace beats Pulse Biosciences on 13 of the 17 factors compared between the two stocks.

How does NeuroPace compare to National Vision?

NeuroPace (NASDAQ:NPCE) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

NeuroPace currently has a consensus target price of $18.83, suggesting a potential upside of 19.88%. National Vision has a consensus target price of $30.08, suggesting a potential upside of 50.57%. Given National Vision's higher possible upside, analysts plainly believe National Vision is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, NeuroPace and NeuroPace both had 1 articles in the media. National Vision's average media sentiment score of 1.70 beat NeuroPace's score of 0.87 indicating that National Vision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Vision	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

National Vision has a net margin of 2.31% compared to NeuroPace's net margin of -21.67%. National Vision's return on equity of 6.41% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
National Vision	2.31%	6.41%	2.81%

NeuroPace has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, National Vision has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

National Vision has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.36	-$21.47M	-$0.65	N/A
National Vision	$1.99B	0.81	$29.60M	$0.57	35.05

78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 2.4% of National Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

National Vision beats NeuroPace on 10 of the 16 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$536.85M	$7.18B	$6.80B	$12.40B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-24.23	49.92	27.08	24.12
Price / Sales	5.36	50.88	516.47	92.58
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	27.56	6.97	10.63	6.23
Net Income	-$21.47M	$162.27M	$3.60B	$331.53M
7 Day Performance	-0.82%	-0.98%	-1.08%	-1.30%
1 Month Performance	0.51%	-1.98%	1.28%	-1.40%
1 Year Performance	67.84%	5.96%	24.71%	18.15%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	2.6808 of 5 stars	$15.71 -0.3%	$18.83 +19.9%	+73.8%	$536.85M	$99.99M	N/A	170
AXGN AxoGen	2.8842 of 5 stars	$39.32 -0.4%	$46.50 +18.3%	+250.0%	$2.09B	$225.21M	N/A	450	Analyst Downgrade
BFLY Butterfly Network	0.8789 of 5 stars	$7.68 -5.2%	$5.56 -27.5%	+258.0%	$1.95B	$97.61M	N/A	460
NVCR NovoCure	2.5014 of 5 stars	$15.74 -2.2%	$23.60 +50.0%	-0.5%	$1.82B	$655.35M	N/A	1,605	Upcoming Earnings
PLSE Pulse Biosciences	1.3235 of 5 stars	$25.70 -0.7%	$30.67 +19.3%	+91.8%	$1.78B	$350K	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. AXGN, BFLY, NVCR, PLSE, and EYE

How does NeuroPace compare to AxoGen?

Summary

How does NeuroPace compare to Butterfly Network?

Summary

How does NeuroPace compare to NovoCure?

Summary

How does NeuroPace compare to Pulse Biosciences?

Summary

How does NeuroPace compare to National Vision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. AXGN, BFLY, NVCR, PLSE, and EYE

How does NeuroPace compare to AxoGen?

Is NPCE or AXGN more profitable?

Does the media refer more to NPCE or AXGN?

Which has preferable valuation and earnings, NPCE or AXGN?

Do analysts rate NPCE or AXGN?

Which has more volatility and risk, NPCE or AXGN?

Do institutionals and insiders have more ownership in NPCE or AXGN?

Summary

How does NeuroPace compare to Butterfly Network?

Do analysts prefer NPCE or BFLY?

Do institutionals & insiders hold more shares of NPCE or BFLY?

Which has stronger valuation & earnings, NPCE or BFLY?

Is NPCE or BFLY more profitable?

Does the media refer more to NPCE or BFLY?

Which has more volatility and risk, NPCE or BFLY?

Summary

How does NeuroPace compare to NovoCure?

Which has better earnings and valuation, NPCE or NVCR?

Do institutionals and insiders hold more shares of NPCE or NVCR?

Is NPCE or NVCR more profitable?

Does the media refer more to NPCE or NVCR?

Do analysts prefer NPCE or NVCR?

Which has more volatility & risk, NPCE or NVCR?

Summary

How does NeuroPace compare to Pulse Biosciences?

Which has stronger earnings & valuation, PLSE or NPCE?

Do analysts prefer PLSE or NPCE?

Is PLSE or NPCE more profitable?

Does the media favor PLSE or NPCE?

Do insiders and institutionals believe in PLSE or NPCE?

Which has more risk and volatility, PLSE or NPCE?

Summary

How does NeuroPace compare to National Vision?

Do analysts rate NPCE or EYE?

Does the media prefer NPCE or EYE?

Is NPCE or EYE more profitable?

Which has more volatility and risk, NPCE or EYE?

Which has stronger earnings & valuation, NPCE or EYE?

Do insiders & institutionals hold more shares of NPCE or EYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools